Advisors Asset Management Inc. bought a new stake in Stryker Corporation (NYSE:SYK - Free Report) during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 91,651 shares of the medical technology company's stock, valued at approximately $25,240,000.
A number of other institutional investors and hedge funds have also added to or reduced their stakes in SYK. State Street Corp grew its holdings in shares of Stryker by 1.2% in the 2nd quarter. State Street Corp now owns 15,532,565 shares of the medical technology company's stock worth $4,903,772,000 after purchasing an additional 183,400 shares during the last quarter. Wellington Management Group LLP increased its position in shares of Stryker by 0.6% during the 2nd quarter. Wellington Management Group LLP now owns 8,167,185 shares of the medical technology company's stock worth $2,571,357,000 after purchasing an additional 45,478 shares in the last quarter. Bank of America Corp DE bought a new position in Stryker during the 2nd quarter valued at about $1,404,284,000. Royal Bank of Canada lifted its holdings in Stryker by 6.5% during the 1st quarter. Royal Bank of Canada now owns 3,273,232 shares of the medical technology company's stock valued at $1,075,552,000 after purchasing an additional 199,863 shares during the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its position in Stryker by 21.8% in the second quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 2,689,376 shares of the medical technology company's stock valued at $846,723,000 after buying an additional 481,175 shares in the last quarter. Institutional investors own 77.09% of the company's stock.
Insiders Place Their Bets
In related news, Director Ronda Stryker sold 550,000 shares of the business's stock in a transaction that occurred on Friday, November 6th. The shares were sold at an average price of $325.32, for a total value of $178,926,000.00. Following the completion of the transaction, the director owned 1,701,375 shares in the company, valued at $553,491,315. The trade was a 24.43% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. 4.60% of the stock is owned by company insiders.
Wall Street Analyst Weigh In
Several analysts have weighed in on SYK shares. UBS Group decreased their price objective on shares of Stryker from $400.00 to $382.00 and set a "buy" rating on the stock in a research note on Monday, August 3rd. BMO Capital Markets reiterated an "outperform" rating and issued a $309.00 target price (down from $317.00) on shares of Stryker in a research note on Friday, October 30th. BTIG Research boosted their target price on Stryker from $304.00 to $345.00 and gave the stock a "buy" rating in a report on Wednesday. Barclays decreased their price target on Stryker from $375.00 to $365.00 and set an "overweight" rating on the stock in a research report on Friday, October 30th. Finally, Weiss Ratings reaffirmed a "hold (c)" rating on shares of Stryker in a report on Thursday, October 29th. Twenty-one equities research analysts have rated the stock with a Buy rating and seven have given a Hold rating to the company's stock. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $343.77.
View Our Latest Stock Analysis on Stryker
Stryker Stock Down 1.6%
Shares of NYSE:SYK opened at $313.17 on Friday. The company has a quick ratio of 1.30, a current ratio of 2.18 and a debt-to-equity ratio of 0.60. The firm has a market cap of $119.22 billion, a P/E ratio of 33.35, a P/E/G ratio of 2.18 and a beta of 0.78. Stryker Corporation has a 12 month low of $267.00 and a 12 month high of $389.33. The company's 50-day moving average price is $294.97 and its two-hundred day moving average price is $321.64.
Stryker (NYSE:SYK - Get Free Report) last announced its earnings results on Thursday, October 29th. The medical technology company reported $3.52 earnings per share for the quarter, missing analysts' consensus estimates of $3.55 by ($0.03). Stryker had a return on equity of 23.74% and a net margin of 13.78%. The company had revenue of $6.52 billion during the quarter, compared to the consensus estimate of $6.62 billion. During the same period in the prior year, the firm posted $3.19 earnings per share. The company's revenue was up 7.6% on a year-over-year basis. As a group, research analysts forecast that Stryker Corporation will post 14.85 EPS for the current fiscal year.
About Stryker
(
Free Report)
Stryker is a medical technology company that develops and sells products and services for healthcare providers. Its offerings include orthopedic implants and surgical equipment, neurotechnology and spine products, and medical and surgical equipment used in hospitals and other care settings. The company's products also include patient-handling and emergency medical equipment, as well as instruments and technologies that support surgical procedures. Stryker serves healthcare customers in the United States and internationally.
Further Reading

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Stryker, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Stryker wasn't on the list.
While Stryker currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.